The purpose of the present study was to investigate the role of P-glycoprotein (P-gp) in drug disposition in skin. The distribution of P-gp substrates (rhodamine 123 and itraconazole) to the skin after administration from the epidermal side was lower in P-gp gene knockout (mdr1a/1b -/-) mice than that in wild-type mice. Coadministration of propranolol, a P-gp inhibitor, decreased the distribution of itraconazole to the skin in wild-type mice, but not in mdr1a/1b -/-mice. These results suggest that P-gp contributes to the influx (from the epidermal side) of its substrates into skin, although P-gp is generally involved in efflux of drugs from various tissues. This finding was supported by the lower vectorial transport of rhodamine 123 from the epidermal to the hypodermal side in mdr1a/1b -/-mice in Ussing-type chamber experiments and by the immunohistochemical localization of P-gp throughout the dermal layer. Distribution of itraconazole after intravenous administration, on the other hand, was higher in mdr1a/1b -/-mice than that in wild-type mice, suggesting that P-gp transports this drug from the skin to the circulation. The present findings are the first to demonstrate involvement of P-gp in dermal drug disposition.
Introduction
Skin acts as a barrier against environmental stress and plays pivotal roles in homeostasis, including maintenance of body temperature and water balance. Stratum corneum (SC), the outermost layer of skin, is generally considered as a major barrier against environmental stress, and penetration of xenobiotics through the epidermal layer is quite limited due to the SC structure, which includes multiple lipid lamellae [1] . In addition to such physical barriers, there is increasing evidence that skin epithelial cells contain biochemical barrier systems [2] [3] [4] [5] . These include metabolic enzymes expressed in skin keratinocytes that convert various types of xenobiotic compounds into hydrophilic metabolites, which can then be pumped out of the body [2] [3] [4] [5] .
Xenobiotic transporters have broad substrate specificity, and are involved in both uptake (influx) and secretion (efflux), thereby affecting cellular disposition of their substrates [6] .
Therefore, it would be reasonable that both metabolic enzymes and transporters are expressed in skin to act cooperatively as barrier systems against environmental stress and toxins. Indeed, several transporter genes are expressed in both mouse and human skin [2, 7, 8] .
Interplay between a metabolic enzyme, cytochrome P450 3A, and an ATP binding cassette (ABC) transporter, P-glycoprotein (P-gp/ABCB1), has been suggested to occur in the metabolism and secretion of xenobiotics in a certain organ [9] . ABC transporters are one of the major xenobiotic transporter superfamilies and use ATP hydrolytic energy as a driving force for efflux pumping of various types of compounds [10] . Although such an interplay has not been demonstrated in skin, the functional expression of one of the ABC transporters, multidrug resistance-associated protein 1 (MRP1/ABCC1), in mouse skin was recently demonstrated by using mrp1 gene knockout mice, which exhibited an increase in the accumulation of two MRP1 substrates, fluo 3 (1-[2-amino-5-(2,7-dichloro-6-hydroxy-3-oxo-9-xanthenyl)phenoxy]-2-(2-amino-5-methylphenoxy)ethane-N, N, N, N-tetraacetic acid) and grepafloxacin, in the skin compared with wild-type mice, suggesting that Mrp1 is involved in efflux of these compounds from the skin [11] .
Organic anion transport system(s) have also been proposed to be involved in transdermal absorption of flurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID) which exhibits higher transdermal permeability than other NSAIDs [12] . P-gp is another well-characterized ABC transporter which accepts various types of compounds as substrates [13] . It is a product of multidrug resistance (MDR1) gene in humans, whereas two subtype genes, mdr1a and mdr1b, are present in mice [13] . P-gp functions as an efflux pump for various drugs in tissues such as brain, intestine and kidney [13] . In particular, the distribution to the brain of various drugs is greatly limited by the function of P-gp expressed in brain capillary endothelial cells [14, 15] . Despite the accumulated information on the fundamental role of P-gp in drug disposition, the function and expression of P-gp in the skin have not yet been fully characterized. We have already detected gene expression of MDR1 in human skin, and mdr1a and mdr1b in mouse skin [8] . P-gp was also detected immunohistochemically in human skin and neonatal mouse skin [2, 16] . The cooperative increase in the expression of P-gp and P450 3A in skin in response to dexamethasone treatment may imply an interplay between P-gp and metabolic enzymes in skin [2] . However, there is no report about the role of P-gp in drug disposition in the skin. Considering the clinical importance of transdermal therapeutic systems, it seems important to investigate the transport mechanism underlying transdermal drug permeation.
The purpose of the present study was to clarify the role of P-gp in drug disposition in skin, focusing on transdermal drug permeation from the epidermal side and on drug distribution from circulating blood to the skin by using P-gp gene knockout (mdr1a/1b -/-) mice. To investigate the role of P-gp, the transdermal permeation of P-gp substrates was first examined by means of an Ussing-type chamber method in both absorptive and secretory directions. To further investigate the contribution of P-gp in vivo, P-gp substrates were transdermally or intravenously administered, and the concentrations in skin and plasma were analyzed. To more clearly observe the function of P-gp in the skin, we performed the Ussing-type chamber experiment and in vivo transdermal administration with tape-stripped mouse skin from which the stratum corneum had been removed, because transporters would function in viable skin layer (viable epidermis and dermis), but not in stratum corneum that consists of dead cells. In addition, we reported that the Ussing-type chamber method with tape-stripped skin may be useful to investigate the role of carrier-mediated transport systems in transdermal drug permeation [12] .
Materials and methods

Materials
Rhodamine 123 (2-[6-amino-3-imino-3H-xanthen-9-yl]benzoic acid methyl ester) and FITC-dextran (fluorescein isothiocyanate-dextran) were purchased from Sigma Chemical Co. Ltd. Wako Pure Chemical Industries Ltd. (Osaka, Japan). All other reagents were commercial products of reagent grade, and were used without further purification.
Animals
Six-to nine-week-old male FVB/mdr1a/1b -/-and FVB/ mdr1a/1b +/+ mice were purchased from Taconic (Germantown, NY, USA) and CLEA Japan Inc. (Tokyo, Japan), respectively. The mice were kept in a temperature-and light-controlled environment with standard food and tap water provided ad libitum. Animal experiments were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals in Kanazawa University. Three days before experiments, mouse was anesthetized with 1.3 µL/g body weight of sodium pentobarbital (64.8 mg/mL) subcutaneously administered, and the fur over the abdominal skin was removed using an electric hair clipper and depilatory cream.
Transdermal permeation assessed with an Ussing-type chamber
The permeation experiments were performed by means of an Ussing-type chamber method with tape-stripped mouse skin [12] . Briefly, a mouse was sacrificed under ether anesthesia, and the abdominal skin was stripped using vinyl tape (Nichiban Co., Tokyo, Japan) until the surface glittered (8 times The volume of the bathing solution on both sides was 1.2 mL, and the solutions were kept at 37°C
and gassed with 95% O 2 / 5% CO 2 to maintain tissue viability during experiments.
To measure the transdermal permeation, rhodamine 123 or FITC-dextran was applied to the hypodermal or epidermal side, and 0.3 mL of solution was withdrawn from the opposite side and replaced with an equal volume of fresh solution at the designated times. The fluorescence of samples was measured using fluorescence plate reader (Tecan Spectrafluor Plus, Tecan Austria, Salzburg, Austria). To compare the permeability through the skin between the two different compounds that were applied at different doses into the donor side, the transdermal permeability was represented as the distribution volume that was calculated by dividing the amount of drug permeated by the concentration of drug applied to the donor side. Namely, the permeated amount per unit area (pmol/cm 2 ) was divided by the concentration in the applied solution (µM) and shown as distribution volume per unit area (µL/cm 2 ).
Transdermal permeation experiments in vivo
Rhodamine 123 and FITC-dextran were dissolved in saline (0.4 and 5 mg/mL, respectively) and itraconazole was dissolved in dimethyl sulfoxide (DMSO, 0.5 mg/mL). The solution was applied to a patch for transdermal administration (16 mm diameter, Torii Pharmaceutical Co. Ltd., Tokyo, Japan). A mouse was anesthetized with sodium pentobarbital, the abdominal skin was stripped, and the patch was applied to the stripped region. At 6 h after dosing of rhodamine 123 and FITC-dextran, mice were sacrificed under ether anesthesia, and the abdominal skin and the blood were collected. Skin and blood were also collected at 18 h after dosing of itraconazole. To compare the absolute values in skin distribution between two compounds at different doses, tissue distribution was represented as distribution volume. Namely, the distributed amount of drug per skin weight (ng/mg skin) was divided by the drug concentration in the solution (mg/mL) applied in transdermal administration or that in circulating plasma (µg/mL) after intravenous administration, and shown as distribution volume per skin weight (nL or µL/mg skin).
Distribution of itraconazole to the skin after intravenous administration
Intravenous administration of itraconazole was performed according to the method of Itraconazole concentration in plasma and tissues was measured by HPLC as reported [20] [21] [22] , with some modifications. A plasma sample was spiked with the internal standard, clotrimazole, and buffered at pH 7.8 with 0.05 M KH 2 PO 4 . After vortex-mixing, extraction was performed twice with 4 mL of heptane-isoamyl alcohol (98.5 : 1.5, v/v). The organic phase was back-extracted with 3 mL of 0.05 M H 2 SO 4 and removed. The remaining acidic phase was alkalinized to pH 9 with 25% ammnonia solution, and extraction was performed twice with 4 mL of heptane-isoamyl alcohol mixture again. The organic phase was evaporated to dryness under a stream of nitrogen at 55 ˚C. The residue was dissolved in the mobile phase and injected into the HPLC. A skin sample was homogenized in 0.5 mL of purified water and spiked with the internal standard. Then 0.5 mL of 5 N NaOH was added to the homogenized sample, and the sample was solubilized for 15 min at 75 ˚C. Next, 1 mL of 5 M ammonium acetate was added to the lysate, and the sample was extracted in the same way as described for plasma. Lung and brain samples were homogenized in 0.36 and 0.6 mL of purified water, respectively, and each homogenized sample was extracted as described in the case of plasma. The UV detector (JASCO UV-2075 Plus) was set at 263 nm. A reversed-phase column, COSMOSIL 5C18-MS-II (4.6 x 150 mm; Nacalai Tesque, Inc.), was used with a mobile phase of 0.05 % diethylamine in water and acetonitrile (40 : 60, v/v). The flow rate was 1.0 mL/min. Tissue-to-plasma concentration ratio of itraconazole was calculated by dividing the tissue concentration by the plasma concentration.
To measure FD-4 concentration, a skin sample was homogenized in 0.5 mL of purified water. Then 0.5 mL of 5 N NaOH was added to the homogenized sample, and the sample was solubilized for 15 min at 75˚C. Next, 1 mL of 5 M ammonium acetate and 2 mL of heptane-isoamyl alcohol (98.5 : 1.5, v / v) were added to the lysate. The mixture was shaken for 30 min, and centrifuged at 1000 g for 10 min. The organic phase was removed, and 2 mL of heptane-isoamyl alcohol mixture was added to the water layer. After shaking and centrifugation, the organic phase was removed, and the fluorescence of the water phase was measured using a fluorescence plate reader.
Immunocytochemical analysis
Immunostaining of P-gp in mouse skin was performed according to the method of All experiments were performed at least three times. Data are expressed as mean ± S.E.M.
Student's t-test was used to determine the statistical significance of differences between two groups.
One-way analysis of variance (ANOVA) followed by Dunnett's test was used to determine the statistical significance in comparisons of more than two groups. A p value of less than 0.05 was considered as statistically significant. of rhodamine 123 in mdr1a/1b -/-mice was significantly lower than that in wild-type mice (Fig. 1A) .
On the other hand, the secretory permeation (from the hypodermal to epidermal side) of rhodamine 123 in mdr1a/1b -/-mice was significantly higher than that in wild-type mice (Fig. 1B) . Rhodamine 123 permeation in wild-type mice thus occurred preferentially in the absorptive direction, whereas that in mdr1a/1b -/-mice did not (Fig. 1A, 1B) . The transdermal permeation of FD-4 was similar in wild-type and mdr1a/1b -/-mice in both directions (Fig. 1C, 1D ). The rhodamine 123 permeation in both strains were higher than that of FD-4, indicating that the transcellular pathway might be the major route for the transdermal permeation of rhodamine 123.
Transdermal permeation of rhodamine 123 and itraconazole in vivo
To further examine the permeation of P-gp substrates in the absorptive direction in vivo, a patch for transdermal administration was employed. Fig. 2 shows the distribution of rhodamine 123
and FD-4 to the skin after transdermal administration. The distribution of rhodamine 123 in mdr1a/1b -/-mice was significantly lower than that in wild-type mice ( Fig. 2A) . On the other hand, the distribution of FD-4 was similar in wild-type and mdr1a/1b -/-mice (Fig. 2B) , and lower than that of rhodamine 123, indicating that the difference in skin distribution of rhodamine 123 between the two strains cannot be explained simply by a difference in the distribution to extracellular space.
Plasma concentration of rhodamine 123 was below the detection limit at all the sampling points (< 10 ng/mL of plasma) probably because of small amount applied (~ 40 µg) to the patch due to the dissolution limit of rhodamine 123 in saline.
To further support the involvement of P-gp, the distribution of itraconazole was examined in vivo. Itraconazole is applied for the treatment of fungal infections of the skin and is known to be a P-gp substrate [18, 24, 25] . Fig. 3 shows that the distribution of itraconazole to the skin after transdermal administration was significantly lower in mdr1a/1b -/-mice than that in wild-type mice.
The effect of P-gp inhibitors on the distribution of itraconazole to the skin was then examined. In a preliminary study, the effect of the P-gp substrates or inhibitors verapamil, propranolol and celiprolol [25] [26] [27] was examined in wild-type mice. Coadministration of each of them decreased the distribution of itraconazole to the skin, but propranolol had the greatest effect (data not shown). In addition, propranolol is the potential candidate for the transdermal drug delivery [28] , since oral bioavailability of propranolol is quite low due to significant first-pass hepatic metabolism [29] , but propranolol may be permeable through the skin at least to some extent [28] . Therefore, the effect of propranolol was further examined in both wild-type and mdr1a/1b -/-mice. The distribution of itraconazole was decreased by the coadministration of propranolol in wild-type mice, but not in mdr1a/1b -/-mice (Fig. 3) . In our preliminary study, more typical P-gp inhibitor like varapamil than propranolol had weaker effects on the distribution of itraconazole to the skin. Although the reason for this finding is unknown, permeability of inhibitors themselves through the skin may also have to be considered to discuss potential inhibition of P-gp functionally expressed in the skin, because not only the affinity of inhibitors for P-gp, but also the concentration of inhibitors available in the skin would affect the inhibition potential for P-gp expressed in the skin. Plasma concentration of itraconazole was below the limit of detection (< 0.5 µg/mL of plasma).
Distribution of itraconazole from circulating blood to the skin
To examine the skin distribution from the blood side, itraconazole was intravenously administered, and both plasma concentration and skin distribution were determined (Fig. 4) . The plasma concentration of itraconazole was similar in wild-type and mdr1a/1b -/-mice (Fig. 4A) , whereas the tissue-to-plasma concentration ratio at 60 min after administration in the skin of mdr1a/1b -/-mice was significantly higher than that in wild-type mice (mdr1a/1b -/-/wild-type ratio = 1.4). The tissue-to-plasma concentration ratio in the brain of mdr1a/1b -/-was also significantly higher than that in wild-type mice, whereas that in the lung of mdr1a/1b -/-tended to be higher, but not significantly so, than that in wild-type mice. Such differences in the contribution of P-gp between brain and lung were in good agreement with reported data [18] .
Localization of P-gp in mouse skin
Although we have already demonstrated gene expression of mdr1a and mdr1b in mouse skin [8] , information on the localization of their gene products is limited. Fig. 5 shows the result of immunohistochemical analysis of P-gp in mouse skin. P-gp was observed throughout the dermal and hypodermal (subcutaneous) layers of wild-type mice, while fluorescence staining was absent in those layers of mdr1a/1b -/-mice (Fig. 5) . Fluorescence observed in the cornified layer could be nonspecific since it was observed not only in wild-type mice, but also in mdr1a/1b -/-mice (Fig. 5) . It was previously reported that immunoreactive staining against P-gp antibody was detected in the epidermis and the eccrine part of the sweat glands [2, 16, 30] . In the present study, on the other hand, the expression of P-gp was mainly detected in the dermis, but unclear in the epidermis or the eccrine part of the sweat glands. It is generally considered that substances tend to enter the bloodstream via the capillary bed near to the epidermal-dermal junction after transdermal administration. Therefore, if P-gp is only expressed in dermis and/or hypodermis, P-gp may not play fundamental role in transdermal absorption of its substrate to the bloodstream. However, the present finding alone cannot rule out the possibility of the expression of relatively lower amount of P-gp in epidermis, since the detection of P-gp in epidermis may be hindered due to the much higher P-gp expression in dermis and hypodermis regions. Further studies are necessary to clarify physiological role of P-gp expressed in each region of the skin.
Discussion
P-gp has been shown to be involved in drug distribution and excretion in various organs, including intestine, liver and kidney [13] . Nevertheless, the contribution of P-gp to transdermal drug permeation has remained unknown. In the present study, we demonstrate that P-gp contributes to the in vivo transport of substrates in the absorptive direction in skin (Figs. 2, 3) . Specifically, after transdermal administration, the distribution of rhodamine 123 and itraconazole to the skin in mdr1a/1b -/-mice was lower than that in wild-type mice (Figs. 2A, 3 ), whereas that of FD-4 was similar in the two strains (Fig. 2B) . Further, the coadministration of propranolol (a P-gp inhibitor)
decreased the itraconazole distribution in skin in wild-type mice, but not in mdr1a/1b -/-mice (Fig. 3) .
These results suggest that P-gp contributes to itraconazole absorption into the skin after transdermal administration. This finding was unexpected, since P-gp is generally considered to play a role as a barrier system to pump out xenobiotic compounds from the body. However, the occurrence of P-gp-mediated absorption was also supported by Ussing-type chamber studies: the transdermal permeation of rhodamine 123 in wild-type mice was shown to be vectorial, favoring the absorptive direction, whereas that in mdr1a/1b -/-mice was not (Fig. 1A, 1B) . No vectorial permeation of an extracellular marker, FD-4, was observed in either of the strains (Fig. 1, C, D) . In the transdermal administration of itraconazole, DMSO was used as a vehicle according to the previous reports [31, 32] . On the other hand, DMSO was reported to extract lipids and interact with keratin in the skin [33] . Therefore, the skin damage cannot be excluded during the transdermal administration of itraconazole for 18 h in the present study. However, there was no obvious morphological difference in the skin at the end of transdermal administration between itraconazole and rhodamine 123 (administered for 6 h using saline as a vehicle). In addition, the difference in distribution of itraconazole to the skin was observed between wild-type and mdr1a/1b -/-mice (Fig. 3) . Therefore, the present finding may suggest possible involvement of P-gp in distribution of itraconazole to the skin, although further studies using other P-gp substrates and solvents are necessary to confirm this hypothesis.
On the other hand, when itraconazole was intravenously administered, the tissue-to-plasma concentration ratio in the skin was significantly higher in mdr1a/1b -/-mice than that in wild-type mice, as in the case of brain (Fig. 4, B) . In brain, P-gp is expressed on luminal membranes of capillary endothelial cells and exports its substrates into the blood [14, 15] . Similarly, the present findings can be explained if we consider that P-gp is involved in the efflux of its substrates from skin to blood. Verapamil, a P-gp substrate, inhibited the efflux of rhodamine 123 in fibroblasts isolated from human dermis [34] , also supporting the existence of P-gp-mediated efflux.
Although the physiological role of P-gp-mediated efflux from skin to the blood is unknown, it should be noted that skin has a large organ volume (more than twice that of the liver), of which 30% represents interstitial fluid that contains albumin at a similar level to that in plasma [35, 36] .
Skin may therefore act as a storage depot for hydrophobic xenobiotics. In addition, various types of metabolic enzymes that also recognize xenobiotic compounds are expressed in skin [2] [3] [4] [5] . Therefore, the skin may play a role in capturing the xenobiotic compounds present in the circulating blood, and converting them into hydrophilic metabolites. In the skin, not only P-gp, but also other ABC transporters, MRP1 and BCRP, are functionally expressed [2, 8, 11, 37] . Therefore, these efflux transporters may contribute to the export of such metabolites into circulating blood. In addition, the passive influx and subsequent P-gp-mediated efflux might enhance the efficiency of metabolism, because the blood flow rate per organ volume in the skin is much smaller than in other organs [35, 36] , so the interplay of enzyme-transporter interactions may be similar to that in the small intestine [9] .
Fluconazole is another triazole antifungal agent that is employed to treat skin infection [38] . A study in guinea pigs indicated that the distribution of itraconazole to the epidermis and hypodermis after systemic administration was much lower than that of fluconazole, even though the plasma concentrations of these drugs are similar [38] . This observation was previously explained in terms of differences in binding to keratin between itraconazole and fluconazole [38] . However, the affinity of itraconazole for P-gp (IC 50 < 3 µM) is much higher than that of fluconazole (IC 50 > 400µM) [25, 39] . Therefore, our present finding regarding the contribution of P-gp to the transport of itraconazole from skin to blood may indicate that P-gp expressed in the skin effectively transports itraconazole from skin to blood, resulting in a lower distribution to the skin, compared with that of fluconazole.
Involvement of P-gp in drug absorption in the skin could have significant implications for drug development, given that P-gp has a broad substrate specificity [13] . Oral administration of P-gp substrates can be problematic, since intestinal P-gp limits their absorption from the intestinal tract [6] . In skin, on the other hand, P-gp may serve to increase distribution from the epidermal side to the skin (Figs. 2, 3 ). This finding may have impact on the selection of a suitable administration route for P-gp substrates. In addition, several single-nucleotide polymorphisms in MDR1 gene are known to alter the expression and/or function of P-gp [13] . This may cause interindividual differences in the kinetics of drug disposition in the skin. For example, sparfloxacin and levofloxacin, both of which are fluoroquinolones and P-gp substrates, cause adverse dermatological reactions, such as photosensitivity dermatitis [40, 41] . Further analysis should be performed to clarify the possible relevance of P-gp to such adverse reactions. In the present study, however, plasma concentrations of rhodamine123 and itraconazole after transdermal administration were below the limit of detection, probably because of limited permeation of these compounds through the skin. In addition, the present analysis has not yet analyzed details in substrate specificity of P-gp functionally expressed in the skin. Only limited numbers of substrate and inhibitor of P-gp were used in the present study because of the limited permeability of commercially available P-gp substrates through the skin. Therefore, the present finding is the first step to clarify the involvement of P-gp in dermal drug disposition. Investigations using more permeable drugs will also be necessary to demonstrate important implications of P-gp for the delivery of therapeutic agents into and through the skin.
It should be noted that the phenotype regarding skin distribution in mdr1a/1b -/-mice was different between transdermal and intravenous administrations. The distribution to the skin was decreased by mdr1a/1b -/-knockout after transdermal administration (Fig. 2, 3 ), whereas it was increased after intravenous injection (Fig. 4) . Possible explanations include uneven localization of P-gp, leading to a difference in the contributions of P-gp to permeability from the epidermal side into the skin and from skin to blood. In the present study, immunohistochemical analysis revealed that P-gp is expressed in dermis, although the polarity of P-gp expression in the dermal cells was not clearly observed (Fig. 5) . The skin consists of multilayers of various differentiated and undifferentiated cells, and therefore the distribution of localization and/or function of transporters also needs to be clarified.
In the present study, stratum corneum had been removed by tape-stripping despite the poor permeability barrier of mouse skin compared to human skin. In clinical applications, skin is rarely tape-stripped prior to application of a transdermal patch. Furthermore, it is believed that stratum corneum is the rate-determining step for the transdermal permeation of most drug molecules. Therefore, further study with intact skin is needed to investigate the clinical relevance of the P-gp function in the skin. In addition, to avoid possible saturation of P-gp, we attempted to use the lowest concentration of rhodamine 123 in Usssing-type chamber by considering the detection limit. Therefore, the substrate concentration in the present study may be much lower than that typically applied in transdermal systems. Since the contribution of P-gp in dermal drug disposition may depend on the substrate concentration, investigations using P-gp substrates at clinically relevant concentration range are also needed to clarify clinical implication of P-gp in transdermal drug delivery.
In conclusion, our present findings indicate that P-gp contributes to the transport of its substrates both from the epidermal side into the skin, and from skin to blood. Because many drugs are reported to be substrates for P-gp [13] , it is also implied that P-gp contributes to the dermal disposition of other P-gp substrates than rhodamine 123 and itraconazole. Therefore, further studies in intact skin with stratum corneum are needed to clarify clinical implications of P-gp for the delivery of therapeutic agents into and through the skin. When error bars are not shown, they were smaller than the symbols.
Figure legends
Fig. 5
Immunohistochemical analysis of P-gp expression in skin from wild-type and mdr1a/1b -/-mice Cryosections (10 µm) of skin from wild (A) and mdr1a/1b -/-mice (B) were incubated with anti-P-gp antibody (C219) followed by goat anti-mouse Alexa 488 (green signal). Both sections were counter-stained for nuclei with DAPI (blue signal). 
